Navigation Links
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema
Date:3/4/2009

h HAE. C1 inhibitor therapy has been used acutely for more than 30 years in Europe to treat patients with C1 inhibitor deficiency. Cinryze has not been approved for acute treatment in the United States or any other jurisdiction.

Cinryze has been well tolerated. The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patie
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
2. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
3. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. ViroPharma Provides Update on Vancocin(R)
5. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
6. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
7. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
8. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
9. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... may have effects on genital development in baby boys, a ... to moms with greater exposure to a chemical called DiNP ... between the genitals and anus. Anogenital distance is set in ... androgens ("male" hormones) during pregnancy. The researchers said their ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
(Date:10/29/2014)... A new study has found that certain prostate cancer ... from heart-related causes in men with congestive heart failure ... , the findings will help doctors and patients weigh ... Androgen deprivation therapy (ADT), which reduces levels of male ... cancer cells, is a mainstay of treatment for prostate ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... FOREST, Ill., April 4, 2008 Hospira,Inc. (NYSE: ... today announced that it will host a conference call ... 2008, at 8 a.m. Central,Time., The company will ... stock market open and the conference call., A ...
... Nurses will hold,a news conference Tuesday, April 8, at ... importance of raising the Medicaid reimbursement rates to,help attract ... more,individuals to benefit from the service of care in ... health care services each,week -- equal to the combined ...
... for warning the public of the risk of a ... among law enforcement officers, according to a study by ... Health and the University of Medicine and Dentistry of ... Cop 2 Cop crisis intervention hotline found no statistically ...
... (Nasdaq: IDIX ) announced today that Idenix management,will ... the upcoming,Canaccord Adams Hepatitis C Conference on Wednesday, April ... Hotel in New York, NY., The live and ... "Calendar of Events" in the Idenix Investor Center at, ...
... Ohio) More than 600,000 children participate in school-sponsored ... Yet gymnastics continues to be overlooked in terms of ... injury rates of all girls sports. , A study, ... and Policy (CIRP) at The Research Institute at Nationwide ...
... 4, 2008 Dialysis,Corporation of America (Nasdaq: DCAI ... its eleventh facility in that state., President & ... our growth in Pennsylvania, one of our core markets ... superior quality,care for the patients we are responsible for ...
Cached Medicine News:Health News:Does raising the terrorism alert level cause undue stress? 2Health News:Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania 2
(Date:10/30/2014)... 2014 Molecular Profiles Ltd., a subsidiary of ... Maryland -based Xceleron have announced a ... clinical development that will be launched at AAPS in ... This partnership extends Molecular Profiles, new ROADMAP to ... this month. The company also has complementary collaborations in ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today reported ... Total revenue was $2.4 million and $5.5 million for the three ... $2.5 million for the same periods in 2010. Total ... 2011, were $7.6 million and $15.0 million as compared to $6.1 ...
... 2011 CORRECTED -- Bionovo, Inc. (NASDAQ: BNVI ... the three months ended June 30, 2011. ... drug candidate, MF101, or Menerba™, during the past quarter, delivering ... and Chief Executive Officer. "We have completed the tasks which ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 2CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 3CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 4CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 5
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: